Revvity launches CE-IVDR-certified GSP T1D 3plex kit to identify at-risk children before symptoms appear, leveraging existing platforms amidst market optimism and investor caution.
Revvity has launched its GSP T1D 3plex kit, a diagnostic system aimed at helping identify children at risk of type 1 diabetes before symptoms emerge, adding a new product to a business already anchored in newborn screening and laboratory automation. According to the company, the CE-IVDR-certified test is designed to automate detection of autoantibodies linked to type 1 diabetes and uses capillary dried blood spots on Revvity’s GSP instrument platform.
The launch matters because type 1 diabetes is often diagnosed only after the immune system has already damaged the pancreas’ insulin-producing beta cells. By shifting screening earlier, Revvity is targeting a stage when intervention may be possible before irreversible harm is done. The company said the kit is intended for population-wide screening programmes and will initially be available in Europe and other markets that recognise CE IVD-marked products.
Revvity’s product strategy fits its wider diagnostics business, which focuses on immunodiagnostic assays and newborn screening tools. The company, based in Waltham, Massachusetts, was formed in 2023 after PerkinElmer rebranded its life sciences and diagnostics operations. That background gives the new kit a clear commercial logic: it leverages an existing instrument base rather than requiring a completely new platform for screening laboratories.
Investors, however, are already pricing in a good deal of optimism. GuruFocus said Revvity’s shares traded at $142.11, about 20.9% above its GF Value estimate of $117.55, a sign it considers the stock modestly overvalued. The same analysis put the company’s GF Score at 78 out of 100, suggesting solid overall quality, with momentum and profitability standing out more than growth. GuruFocus also noted that Revvity’s trailing price-to-earnings ratio of 67.48 times is well above its five-year median of 31.84 times.
Ownership trends offer a more cautious read. GuruFocus said five premium investors currently hold Revvity shares, but none have added to their positions recently and all have trimmed holdings in recent quarters. Insider activity has also leaned negative, with about $6.0 million in shares sold over the past 12 months and no insider purchases recorded. That backdrop suggests the market may already have rewarded the company for its recent rally, which has helped push the stock to elevated levels ahead of the kit’s wider rollout.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
